User:Mr. Ibrahem/Silodosin
Clinical data | |
---|---|
Trade names | Urief, Rapaflo, Silodyx, others |
Other names | KAD-3213, KMD-3213 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609002 |
License data | |
Routes of administration | By mouth |
Drug class | α1-adrenoceptor antagonist[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 32% |
Protein binding | 96.6% |
Metabolism | Liver glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement |
Elimination half-life | 13±8 hours[citation needed] |
Excretion | 33.5% renal, 54.9% fecal |
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H32F3N3O4 |
Molar mass | 495.543 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Silodosin, sold under the brand name Rapaflo among others, is a medication used to treat benign prostatic hyperplasia (BPH).[1] It may be used together with a 5α-reductase inhibitor.[2] It is taken by mouth.[1]
Common side effects include retrograde ejaculation, dizziness, low blood pressure with standing, and a stuffy nose.[2] Other side effects may include intraoperative floppy iris syndrome.[1] Use is not recommended in people with significant liver or kidney problems.[2] It is an α1-adrenoceptor antagonist which help muscles in the bladder and prostate relax.[1]
was approved for medical use in the United States in 2008 and in Europe in 2010.[2][1] In the United States 3 month of treatment costs about 34 USD as of 2021.[3]
References[edit]
- ^ a b c d e f g h "Silodyx EPAR". European Medicines Agency (EMA). 2010-01-10. Archived from the original on 2021-05-16. Retrieved 2021-07-27.
- ^ a b c d e "Silodosin Monograph for Professionals". Drugs.com. Archived from the original on 10 August 2020. Retrieved 12 October 2021.
- ^ "Silodosin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 4 May 2016. Retrieved 12 October 2021.